EMCURE · NSE
Emcure Pharmaceuticals Limited
₹2,003.8
+4.92% (+₹94)
Prev. close
₹1,909.8
Volume
17,44,754
Delivery %
65.4%
As of
18 Sept 2026
Price history
Sumeet Bagadia · Choice Equity Broking · 21 Jul 2026
“Bullish on Emcure Pharmaceuticals for the next 1-2 weeks, recommending a buy at ₹1,861 with a target of ₹2,045 and a strict stop loss at ₹1,770. The stock shows strong bullish price action, reversing sharply from 50-day EMA support, forming a higher-low structure with a powerful green candle and a firm daily RSI, favouring continuation.”
Entry ₹1,861Target ₹2,045 (+9.9%)Stop ₹1,770 (-4.9%)R:R 2.0:1Expired undecided · +5.3% since entry
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Emcure Pharmaceuticals for the next 1-2 weeks, recommending a buy at ₹1,861 with a target of ₹2,045 and a str…” | Sumeet BagadiaChoice Equity Broking | Emcure Pharmaceuticals | HIT | ||||
“Bullish on Emcure Pharmaceuticals for the next 1-2 weeks, recommending a buy at ₹1,861 with a target of ₹2,045 and a strict stop loss at ₹1,770. The stock shows strong bullish price action, reversing sharply from 50-day EMA support, forming a higher-low structure with a powerful green candle and a firm daily RSI, favouring continuation.” How it resolved: Emcure Pharmaceuticals price increased from ₹1924.50 to ₹1969.70 (+2.35% in 11d), moving towards the target price. (05 Aug 2026) | |||||||
Fundamentals
About Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Satish Ramanlal Mehta
Headquarters
Pune
Employees
6,914
Website
emcure.comExchange
View on NSE ↗Key stats
Market cap
₹38,014.22 Cr
P/E ratio (TTM)
37.6
Dividend yield
0.19%
EPS (TTM)
₹53.28
Beta (1Y · daily vs NIFTY 50)
0.52
Shares float
4.18 Cr
EPS · quarter ended Jun 2026
₹15.50
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹5,931.08 Cr | ₹6,581.99 Cr | ₹7,896.00 Cr | ₹9,203.54 Cr | |
| EBITDA | — | — | ₹1,170.25 Cr | ₹1,240.33 Cr | ₹1,531.26 Cr | ₹1,845.86 Cr |
| ₹419.00 Cr | ₹662.00 Cr | ₹532.02 Cr | ₹498.18 Cr | ₹681.33 Cr | ₹924.36 Cr | |
| Diluted EPS | — | — | ₹29.43 | ₹27.57 | ₹36.43 | ₹48.77 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹6,768.00 Cr | ₹6,021.00 Cr | ₹6,634.00 Cr | ₹7,709.00 Cr | ₹8,122.00 Cr | ₹9,514.00 Cr | |
| — | — | ₹2,334.30 Cr | ₹2,334.97 Cr | ₹1,022.75 Cr | ₹1,521.24 Cr | |
| Stockholders' equity | ₹2,273.00 Cr | ₹1,988.00 Cr | ₹2,501.00 Cr | ₹2,952.00 Cr | ₹4,446.00 Cr | ₹4,950.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹704.00 Cr | ₹768.00 Cr | ₹747.00 Cr | ₹1,097.00 Cr | ₹852.00 Cr | ₹944.00 Cr | |
| Investing cash flow | — | — | ₹-467.69 Cr | ₹-712.51 Cr | ₹-94.00 Cr | ₹-1,193.06 Cr |
| ₹-189.00 Cr | ₹-152.00 Cr | ₹-145.00 Cr | ₹-164.00 Cr | ₹-814.00 Cr | ₹343.00 Cr | |
| Capital expenditure | ₹-146.00 Cr | ₹-422.00 Cr | ₹-403.00 Cr | ₹-307.00 Cr | ₹-407.00 Cr | ₹-548.00 Cr |
| End cash position | — | — | ₹-174.53 Cr | ₹43.99 Cr | ₹-14.31 Cr | ₹97.77 Cr |
Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jul 24–Sep 24(2Q) | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25–Mar 26(2Q) | Jun 26 |
|---|---|---|---|---|---|---|---|
| Promoter | 78.08% | 77.94% | 77.92% | 77.91% | 77.88% | 77.87% | 77.83% |
| Public | 21.92% | 22.06% | 22.08% | 22.09% | 22.12% | 22.13% | 22.17% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Emcure Pharmaceuticals Limited | ₹36,230.94 Cr | ₹2,003.8 | 35.8 | 7.32 | 18.7% | 0.31 | +16.7% | +49.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
22 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.